S&P 500   3,006.14 (-0.02%)
DOW   26,885.48 (+0.22%)
QQQ   192.65 (-0.38%)
AAPL   241.40 (+0.37%)
FB   183.74 (-3.17%)
MSFT   137.25 (-0.85%)
GOOGL   1,243.29 (-0.08%)
AMZN   1,767.53 (-1.02%)
NVDA   197.04 (+0.53%)
GE   8.98 (+2.16%)
AMD   31.73 (-0.94%)
NFLX   268.08 (-3.59%)
BAC   31.24 (+0.68%)
GILD   66.20 (+1.52%)
DIS   132.90 (+2.03%)
S&P 500   3,006.14 (-0.02%)
DOW   26,885.48 (+0.22%)
QQQ   192.65 (-0.38%)
AAPL   241.40 (+0.37%)
FB   183.74 (-3.17%)
MSFT   137.25 (-0.85%)
GOOGL   1,243.29 (-0.08%)
AMZN   1,767.53 (-1.02%)
NVDA   197.04 (+0.53%)
GE   8.98 (+2.16%)
AMD   31.73 (-0.94%)
NFLX   268.08 (-3.59%)
BAC   31.24 (+0.68%)
GILD   66.20 (+1.52%)
DIS   132.90 (+2.03%)
Log in

Rhinomed Stock Price, News & Analysis (ASX:RNO)

A$0.26
+0.02 (+8.33 %)
(As of 10/22/2019 02:48 PM ET)
Today's Range
A$0.26
Now: A$0.26
A$0.27
50-Day Range
A$0.22
MA: A$0.28
A$0.32
52-Week Range
A$0.14
Now: A$0.26
A$0.41
Volume3,077 shs
Average Volume122,418 shs
Market Capitalization$36.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rhinomed Limited, a medical technology company, researches, develops, and commercializes consumer and medical devices. The company identifies, acquires, and commercializes late stage therapeutic delivery technologies. It markets Turbine, a nasal dilator designed to assist to breathe easier during aerobic exercise; and Mute, a nasal dilator designed to enhance sleep quality by breathing more and snoring less. The company also develops Breathing Space Health that comprises of a range of wellness programs designed to help people get to sleep. In addition, it develops Sleep Apnea, a clinical trial solution to mild and moderate sleep apnea; creates drug delivery platform for delivering medication into the nose in an inhaled form or via a trans-dermal or trans-mucosal method; and researches and develops current programs focuses on olfactory pathway and wearable technology. The company sells its products through wholesalers, retail stores, and clinics, as well as online in the United States, Canada, the United Kingdom, Taiwan, Australia, and New Zealand. It serves clinicians and health care organizations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Cremorne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-3-84160900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.35 million
Cash FlowA$0.01 per share
Book ValueA$0.03 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$36.90 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RNO News and Ratings via Email

Sign-up to receive the latest news and ratings for RNO and its competitors with MarketBeat's FREE daily newsletter.


Rhinomed (ASX:RNO) Frequently Asked Questions

What is Rhinomed's stock symbol?

Rhinomed trades on the ASX under the ticker symbol "RNO."

Has Rhinomed been receiving favorable news coverage?

News articles about RNO stock have been trending extremely negative on Tuesday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Rhinomed earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Rhinomed.

Who are some of Rhinomed's key competitors?

Who are Rhinomed's key executives?

Rhinomed's management team includes the folowing people:
  • Mr. Michael Johnson, CEO, MD & Director
  • Mr. Sean Slattery, Chief Financial Officer
  • Mr. Phillip Allen Hains, Company Sec.

What is Rhinomed's stock price today?

One share of RNO stock can currently be purchased for approximately A$0.26.

How big of a company is Rhinomed?

Rhinomed has a market capitalization of $36.90 million and generates $3.35 million in revenue each year. View Additional Information About Rhinomed.

What is Rhinomed's official website?

The official website for Rhinomed is http://www.rhinomed.com.au/.

How can I contact Rhinomed?

Rhinomed's mailing address is 97 Green St, RICHMOND, VIC 3121, Australia. The company can be reached via phone at +61-3-84160900.


MarketBeat Community Rating for Rhinomed (ASX RNO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Rhinomed and other stocks. Vote "Outperform" if you believe RNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What does EPS mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel